Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter

Prostate

Volumn 69, Issue 13, 2009, Pages 1422-1434

  Petrigliano, Frank A ^a,c   Virk, Mandeep S ^b   Liu, Nancy ^a   Sugiyama, Osamu ^b   Yu, Duan ^a   Lieberman, Jay R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c NONE   (United States)

Author keywords

Gene therapy; Lentivirus; Prostate cancer; PSCA promoter

Indexed keywords

ANDROGEN; GANCICLOVIR; LENTIVIRUS VECTOR; LUCIFERASE; PRODRUG; PROSTATE STEM CELL ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CELL STRAIN LNCAP; CELL STRAIN MCF 7; CELL SUSPENSION; CELL VIABILITY; CONTROLLED STUDY; HELA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUICIDE GENE; SUICIDE GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; XENOGRAFT;

ANDROGENS; ANIMALS; BREAST NEOPLASMS; CELL SURVIVAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; LENTIVIRUS; LUCIFERASES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, SCID; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69449089095     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20989     Document Type: Article

References (41)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 2000;50(1):7-33.
2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95(17):1276-1299.
3. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000;88(12 Suppl):3009-3014. (Pubitemid 30413184)
4. Long RJ, Roberts KP, Wilson MJ, Ercole CJ, Pryor JL. Prostate cancer: A clinical and basic science review. J Androl 1997; 18(1):15-20. (Pubitemid 27114458)
5. Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman J. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 1997;11(9):1256-1265. (Pubitemid 28041333)
6. Pang S, Dannull J, Kaboo R, Xie Y, Tso CL, Michel K, deKernion JB, Belldegrun AS. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 1997;57(3):495-499.
7. Xie X, Zhao X, Liu Y, Young CY, Tindall DJ, Slawin KM, Spencer DM. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum Gene Ther 2001;12(5):549-561. (Pubitemid 32511076)
8. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 2001;8(9):628-635. (Pubitemid 32912236)
9. Figueiredo ML, Kao C, Wu L. Advances in preclinical investigation of prostate cancer gene therapy. Mol Ther 2007;15(6):1053-1064. (Pubitemid 46813607)
10. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95(4):1735-1740. (Pubitemid 28103463)
11. Saffran DC, Raitano AB, Hubert RS, Witte ON, Reiter RE, Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 2001;98(5):2658-2663. (Pubitemid 32209538)
12. Watabe T, Lin M, Ide H, Donjacour AA, Cunha GR, Witte ON, Reiter RE. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci USA 2002;99(1):401-406. (Pubitemid 34060373)
13. Raff AB, Gray A, Kast WM. Prostate stem cell antigen: A prospective therapeutic and diagnostic target. Cancer Lett 2008;277(2):126-132.
14. Dubey P, Wu H, Reiter RE, Witte ON. Alternative pathways to prostate carcinoma activate prostate stem cell antigen expression. Cancer Res 2001;61(8):3256-3261. (Pubitemid 32695008)
15. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol 2002;16(10):2323-2337. (Pubitemid 35155543)
16. Loimas S, Toppinen MR, Visakorpi T, Janne J, Wahlfors J. Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy. Cancer Gene Ther 2001;8(2):137-144. (Pubitemid 32220978)
17. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256(5063):1550-1552.
18. Nasu Y, Saika T, Ebara S, Kusaka N, Kaku H, Abarzua F, Manabe D, Thompson TC, Kumon H. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 2007;15(4):834-840. (Pubitemid 46432005)
19. McKnight SL. The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene. Nucleic Acids Res 1980;8(24):5949-5964. (Pubitemid 11100297)
20. DeFatta RJ, Li Y, De Benedetti A. Selective killing of cancer cells based on translational control of a suicide gene. Cancer Gene Ther 2002;9(7):573-578. (Pubitemid 34734421)
21. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272(5259):263-267.
22. Yu D, Jia WW, Gleave ME, Nelson CC, Rennie PS. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter. Prostate 2004;59(4):370-382. (Pubitemid 38661804)
23. Berry LJ, Au GG, Barry RD, Shafren DR. Potent oncolytic activity of human enteroviruses against human prostate cancer. Prostate 2008;68(6):577-587.
24. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80(1-2):148-158. (Pubitemid 37272241)
25. Check E. Gene therapy put on hold as third child develops cancer. Nature 2005;433(7026):561. (Pubitemid 40282963)
26. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302(5644):415-419. (Pubitemid 37296260)
27. Pariente N, Morizono K, Virk MS, Petrigliano FA, Reiter RE, Lieberman JR, Chen IS. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther 2007;15(11):1973-1981. (Pubitemid 350011737)
28. Bastide C, Maroc N, Bladou F, Hassoun J, Maitland N, Mannoni P, Bagnis C. Expression of a model gene in prostate cancer cells lentivirally transduced in vitro and in vivo. Prostate Cancer Prostatic Dis 2003;6(3):228-234. (Pubitemid 37185151)
29. Zhang X, Zhao P, Kennedy C, Chen K, Wiegand J, Washington G, Marrero L, Cui Y. Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells. Cancer Gene Ther 2008;15(2):73-84.
30. Kallifatidis G, Beckermann BM, Groth A, Schubert M, Apel A, Khamidjanov A, Ryschich E, Wenger T, Wagner W, Diehlmann A, Saffrich R, Krause U, Eckstein V, Mattern J, Chai M, Schutz G, Ho AD, Gebhard MM, Buchler MW, Friess H, Buchler P, Herr I. Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer. Cancer Gene Ther 2008;15(4):231-240.
31. Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G, McMillan NA. Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 2006;13(11):1023-1032. (Pubitemid 44564738)
32. Uch R, Gerolami R, Faivre J, Hardwigsen J, Mathieu S, Mannoni P, Bagnis C. Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences. Cancer Gene Ther 2003;10(9):689-695. (Pubitemid 37129456)
33. Iyer M, Salazar FB, Wu L, Carey M, Gambhir SS. Bioluminescence imaging of systemic tumor targeting using a prostate-specific lentiviral vector. Hum Gene Ther 2006;17(1):125-132. (Pubitemid 43100521)
34. Yu D, Scott C, Jia WW, De Benedetti A, Williams BJ, Fazli L, Wen Y, Gleave M, Nelson C, Rennie PS. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter. Cancer Gene Ther 2006;13(1):32-43. (Pubitemid 41816347)
35. Zheng JY, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther 2003;10(10):764-770. (Pubitemid 37243797)
36. Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007;30(4):396-405. (Pubitemid 46684429)
37. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92(8):3439-3443.
38. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8(2):230-239. (Pubitemid 24067110)
39. Chen W, Yan C, Hou J, Pu J, Ouyang J, Wen D. ATRA enhances bystander effect of suicide gene therapy in the treatment of prostate cancer. Urol Oncol 2008;26(4):397-405. (Pubitemid 351885374)
40. Zhang L, Adams JY, Billick E, Ilagan R, Iyer M, Le K, Smallwood A, Gambhir SS, Carey M, Wu L. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther 2002;5(3):223-232. (Pubitemid 34211217)
41. Hattori Y, Maitani Y. Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer. Cancer Sci 2006;97(8)787-798. (Pubitemid 43983792)